The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The Phase II CHEPA trial: brentuximab vedotin, CHP, and etoposide in newly diagnosed CD30+ PTCL
Marek Trněný, MD, Charles University Hospital, Prague, Czech Republic, discusses the Phase II CHEPA trial (NCT05006664), which investigates the efficacy of brentuximab vedotin combined with intensified chemotherapy (etoposide plus CHP) in patients with newly diagnosed CD30-positive peripheral T-cell lymphoma (PTCL). Prof. Trněný highlights that the CHEPA regimen has shown promising results, with a high complete remission rate, translating into encouraging 2-year progression-free survival (PFS) and overall survival (OS) rates. In patients with anaplastic large cell lymphoma, the data were especially exciting: at a median follow-up of 19 months, the 18-month PFS and OS were both 100%. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
